Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker reported strong financial results for Q4 and full year 2021, with net sales up 10.3% year-over-year to $4.7 billion and 19.2% for the year to $17.1 billion. Organic sales rose 9.0% and 12.6% respectively. However, adjusted EPS decreased 3.6% to $2.71. Full-year operating income margin expanded to 25.6%. The company anticipates organic sales growth in 2022 of 6% to 8% despite potential pricing pressures and the ongoing impact of the COVID-19 pandemic.
Stryker (NYSE:SYK) announced a cash tender offer to acquire all outstanding shares of Vocera Communications, Inc. (NYSE:VCRA) for $79.25 per share, initiated on January 25, 2022. This offer follows a merger agreement dated January 6, 2022, and is scheduled to expire on February 22, 2022. The acquisition is contingent on various conditions, including a minimum tender of a majority of Vocera’s shares and regulatory approvals. Vocera's Board of Directors has recommended that its stockholders accept the tender offer. The transaction is expected to close in the first quarter of 2022.
Stryker (NYSE: SYK) has entered into a definitive agreement to acquire Vocera Communications (NYSE: VCRA) for $79.25 per share, totaling approximately $2.97 billion in equity value. The deal enhances Stryker's Medical division by integrating Vocera's innovative digital care coordination platform, which aims to alleviate caregiver burdens and improve patient outcomes. Both companies' boards have unanimously approved the transaction, expected to close in Q1 2022, with a neutral impact on Stryker's 2022 net earnings per share.
Stryker (NYSE:SYK) will host a conference call on January 27, 2022, at 4:30 p.m. ET to discuss its operating results for Q4 2021, with final results released at 4:05 p.m. the same day. Interested parties can register for the call through this link. The call will also be available via a webcast on Stryker's Investor Relations page. A replay will be accessible afterward at provided numbers with a passcode.
Stryker is a global leader in medical technology, focusing on improving healthcare outcomes through innovative products.
Stryker (NYSE:SYK) announced a quarterly dividend increase to $0.695 per share, payable on January 31, 2022, to shareholders of record as of December 31, 2021. This marks a 10.3% increase compared to the previous year and quarter. CEO Kevin Lobo emphasized the company's strong sales growth and solid financial results, aligning with their capital allocation strategy. Stryker is recognized as a leading medical technology firm, focused on improving healthcare through innovative products across Orthopaedics, Medical and Surgical, and Neurotechnology and Spine.
Moss & Gilmore LLP announced a settlement with the U.S. Department of Justice regarding a False Claims Act lawsuit. Defendants Jeffrey M. Gallups, M.D., and Milton Hall Surgical Associates will pay $3,068,434 to resolve allegations of ordering unnecessary medical tests and surgeries for kickbacks. Entellus Medical, acquired by Stryker Corporation (NYSE:SYK), will also pay $1,200,000 for its involvement. Dr. Gallups previously pleaded guilty to healthcare fraud, with sentencing set for February 11, 2022. Failure to pay may result in a $5,388,863 judgment against them.
Stryker reported third-quarter results for 2021, with net sales of $4.2 billion, representing an 11.3% increase from 2020 and a 16.0% increase from 2019. Although organic net sales rose 4.5% year-over-year, reported operating income margin fell by 260 bps to 25.4%. Reported EPS decreased by 30.1% to $1.14, while adjusted EPS rose 2.8% to $2.20. Key segments showed varied growth, with Orthopaedics increasing by 16.1% but experiencing a decline in organic sales. The company adjusted its 2021 outlook, forecasting organic sales growth of 7% to 8% from 2019.
Stryker (NYSE:SYK) will host an Analyst Meeting on November 18, 2021, at 2:30 p.m. ET, in Mahwah, New Jersey. A webcast of the event will be available on Stryker's website, where it will be archived for later viewing. To join via phone, call (844) 200-6205 (domestic) or (929) 526-1599 (international) with access code 695616. A recorded version will be accessible from 8:30 p.m. ET on November 18 until 11:59 p.m. ET on November 25, 2021. For further inquiries, contact their Investor Relations team.
Stryker (NYSE:SYK) will host a conference call on October 28, 2021, at 4:30 p.m. ET to discuss operating results for the quarter ending September 30, 2021. Preliminary results will be released at 4:05 p.m. that day. Participants can join by calling (833) 979-2711 (domestic) or (236) 714-2206 (international) with passcode 7351349. The call will be available via webcast on the company's website and archived after for later access until November 4, 2021.
Stryker is a leading medical technology company focused on enhancing healthcare.
THINK Surgical, Inc. has appointed Stuart F. Simpson as its new president and chief executive officer. With over 24 years at Stryker Corporation (NYSE: SYK), Simpson brings extensive experience in the orthopedic device sector, having previously led the Joint Replacement Division. He is confident about THINK's growth potential, particularly due to its innovative technology and open implant platform, which are believed to drive customer value and operational improvements. The company's robotic system has been used in numerous successful joint replacement surgeries worldwide.